Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.
about
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataPrediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interactionTime-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.Drug-drug interactions in pharmacologic management of gastroparesis.Importance of ALDH1A enzymes in determining human testicular retinoic acid concentrations.Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) modelsRisk assessment of mechanism-based inactivation in drug-drug interactions.Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.Time-dependent CYP inhibition.Cytochrome P450 reaction-phenotyping: an industrial perspective.Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Characterizing metabolic inhibition using electrochemical enzyme/DNA biosensorsIn vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinibMetabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.Methodologies used to identify and characterize interactions among antiepileptic drugs.Advances in predicting CYP-mediated drug interactions in the drug discovery setting.Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir.Prediction and reverse prediction in therapeutics and toxicology.IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4.Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?Risk assessment of drug-drug interactions using hepatocytes suspended in serum during the drug discovery process.Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies.Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors.Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.Modeling Drug Disposition and Drug-Drug Interactions Through Hypothesis-Driven Physiologically Based Pharmacokinetics: a Reversal Translation Perspective.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
P2860
Q27009128-B7560E81-91A8-423C-B27B-454C0370442BQ31044030-759FEB37-D01B-41AC-9279-91404690AB44Q31146882-F3F67A77-653E-430B-85FF-BE47A9A6E955Q33668240-88750043-D01D-4D47-ABB9-7E6989626643Q34476096-9452A9FB-97A5-40CD-B481-4B75477C8CB1Q34480053-2A14AE76-1C34-435B-B6FE-A0F48317C827Q35014265-0EA8068B-BF28-4979-916B-A916DA1ED21BQ35753588-85056DF2-4B4B-4AF7-88D5-62E21E24B300Q36174265-73C44B17-72A3-40C0-85D1-80B178FD2B03Q36328417-CFA227F6-7437-47D2-A76B-FAA099326A09Q36662853-78FC5272-8959-4A94-A585-F115735D11F8Q36717181-B1B824BF-A3D9-476B-A6B7-3B1AB572C134Q36725214-388406B1-9183-4FE7-86B2-57FBB25FB86DQ36960539-2CB9D495-0CD3-48AA-BB4F-11FE452CA20BQ37008900-065365F3-A30B-49A7-A1A2-3CF84B6918C5Q37027004-54E1B88B-1F95-4FC8-BC81-39B7A487AAC4Q37106069-958FBCF2-1DEC-4E60-87C6-19EDA43EEBB8Q37121662-B3E9845A-7D06-497D-B35B-5CAD5E5D9A47Q37198909-12CEAB84-7F15-4D3D-B019-D6FD8EB9B02AQ37237438-264598CD-DC91-4AF2-81F4-4EE2315222E4Q37325594-6629ACEA-DF01-4B7F-B4F5-ABFB2BE63308Q37728849-616B0CB7-22C5-4D8A-9768-0DB103E6D768Q37965706-00156EB5-6719-4F2A-977D-B718A38B764AQ37989979-771698FC-3402-4334-AE8F-24CDBD552E23Q38018676-19B24791-A9D6-492F-B1AE-898B67259858Q38089823-AA5FACCB-2326-4CA6-AC91-5F9DD3EAAC6FQ40192653-5CAECFE7-D6C7-4DB4-9BD7-E1DEB9A9A17EQ42720512-71BB4EE3-893A-4628-97A2-B6F7940B75E4Q43112954-8D29826C-A2A3-4EEF-BF5C-EB69D1B01C8FQ43129481-5950A02E-AED7-494D-87C7-2DA4035F98FFQ43144692-CD599B5B-DF01-406F-8000-C389B948CE2BQ44795024-A990D151-1C90-4144-81CE-4CC48D96B35DQ46135472-AC39B4EA-C2C7-4A8A-997D-290615797621Q47598236-8726109B-9DCD-4DB7-AFBA-8CED34CF9ACBQ47628234-7ACCE2C6-4DCB-499B-BABB-806A95D1AE1DQ47792940-5D4DDC64-6AAB-4E42-9F1D-CDF5663EFD15Q47943718-66E62AE1-B1F8-485E-B1EE-2A7385673C1CQ48173698-B232EB85-EF51-4EF8-BA29-63A489AAC362Q50076374-7DEE361A-AA35-40F3-99C0-F66132064EA5Q52334679-9B23CF3C-26F6-4FF2-AE9B-EFC15803CE8D
P2860
Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prediction of in vivo drug-dru ...... itor absorption rate constant.
@ast
Prediction of in vivo drug-dru ...... itor absorption rate constant.
@en
type
label
Prediction of in vivo drug-dru ...... itor absorption rate constant.
@ast
Prediction of in vivo drug-dru ...... itor absorption rate constant.
@en
prefLabel
Prediction of in vivo drug-dru ...... itor absorption rate constant.
@ast
Prediction of in vivo drug-dru ...... itor absorption rate constant.
@en
P2093
P2860
P1476
Prediction of in vivo drug-dru ...... itor absorption rate constant.
@en
P2093
Hayley S Brown
J Brian Houston
Kiyomi Ito
P2860
P304
P356
10.1111/J.1365-2125.2005.02483.X
P407
P577
2005-11-01T00:00:00Z